Wang Ying, Zhang Weixi, Yin Jinghua, Lu Qianjin, Yin Fei, He Fang, Peng Jing
Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, China.
Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratory of Medical Epigenomics, Changsha, China.
J Neuroimmunol. 2017 Nov 15;312:59-65. doi: 10.1016/j.jneuroim.2017.09.005. Epub 2017 Sep 11.
We analyzed the clinical manifestations of children with anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis in Central South China and the factors influencing the effectiveness of treatment.
A retrospective study of children (0-14years old) with anti-NMDAR encephalitis in Central South China was carried out from March 2014 to November 2016. Demographics, clinical features, treatment, outcome, and the factors influencing the effectiveness of treatment were reviewed.
Fifty-one patients with anti-NMDAR encephalitis were enrolled (age from 4months to 14years old; median age, 8years; 30 females). Forty-five patients (88%) presented with psychiatric symptoms, 40 (78%) with dyskinesia and movement disorders, 39 (77%) with sleep disturbances, 34 (67%) with seizures, 30 (59%) with a decreased level of consciousness (Glasgow score<15), 28 (55%) with speech disturbances, and twelve (24%) with autonomic instability. None presented with hypoventilation, and only one patient (female, 14years old) had an ovarian teratoma. All patients received first-line immunotherapy, 25 patients both received firstline and second-line immunotherapy. Forty-four of the 51 patients achieved good outcomes (score on the modified Rankin Scale [mRS] of 0-2), while the other seven had poor outcomes (mRS score of 3-5).
This study investigated the clinical characteristics of children (aged 14 or younger) with anti-NMDAR encephalitis in Central South China. Patients with decreased consciousness, PICU stay and autonomic instability were more likely to have no or limited response to first-line immunotherapy and to require second-line or even more aggressive immunotherapy. Children with anti-NMDAR encephalitis in China have a much lower incidence of tumors, lower mortality rates, and a lower proportion of lethal autonomic instability than adults.
我们分析了中国中南地区抗N-甲基-D-天冬氨酸受体(抗NMDAR)脑炎患儿的临床表现及影响治疗效果的因素。
对2014年3月至2016年11月中国中南地区0至14岁抗NMDAR脑炎患儿进行回顾性研究。回顾人口统计学、临床特征、治疗、结局及影响治疗效果的因素。
纳入51例抗NMDAR脑炎患者(年龄4个月至14岁;中位年龄8岁;女性30例)。45例(88%)出现精神症状,40例(78%)出现运动障碍,39例(77%)出现睡眠障碍,34例(67%)出现癫痫发作,30例(59%)意识水平下降(格拉斯哥评分<15),28例(55%)出现言语障碍,12例(24%)出现自主神经功能不稳定。无一例出现通气不足,仅1例患者(14岁女性)患有卵巢畸胎瘤。所有患者均接受一线免疫治疗,25例患者同时接受一线和二线免疫治疗。51例患者中有44例获得良好结局(改良Rankin量表[mRS]评分为0至2),另外7例结局较差(mRS评分为3至5)。
本研究调查了中国中南地区14岁及以下抗NMDAR脑炎患儿的临床特征。意识下降、入住儿科重症监护病房及自主神经功能不稳定的患者对一线免疫治疗无反应或反应有限的可能性更大,需要二线甚至更积极的免疫治疗。中国抗NMDAR脑炎患儿的肿瘤发病率、死亡率及致命性自主神经功能不稳定的比例均低于成人。